Pioglitazone improves in vitro viability and function of endothelial progenitor cells from individuals with impaired glucose tolerance.

Pioglitazone improves in vitro viability and function of endothelial progenitor cells from individuals with impaired glucose tolerance.

<h4>Background</h4>Evidence suggests that the PPARγ-agonist insulin sensitizer pioglitazone, may provide potential beneficial cardiovascular (CV) effects beyond its anti-hyperglycaemic function. A reduced endothelial progenitor cell (EPC) number is associated with impaired glucose tolera...

Full description

Bibliographic Details
Main Authors: Valentina Spigoni, Angela Picconi, Monia Cito, Valentina Ridolfi, Sabrina Bonomini, Chiara Casali, Ivana Zavaroni, Luigi Gnudi, Marco Metra, Alessandra Dei Cas
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23139771/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23139771/?tool=EBI

Similar Items